Navigation Links
Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting

Initial Physician Experience with Eculizumab in Patients with Other Rare Complement-Mediated Diseases also to be Presented

CHESHIRE, Conn., Nov. 10 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the American Society of Hematology (ASH) has published additional data relating to Soliris(R) (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Data also have been published regarding initial experience with eculizumab in patients with two other rare diseases (Atypical Hemolytic Uremic Syndrome and Cold Agglutinin Disease). Abstracts will be presented at the 50th Annual Meeting of the American Society of Hematology, to be held December 6 to 9, 2008 at the Moscone Center in San Francisco.

The following abstracts will be presented as oral presentations on Monday, December 8, 2008. The abstracts and presentation information can be accessed through the links provided below.

-- "Eculizumab Therapy Results in Rapid and Sustained Decreases in

Markers of Thrombin Generation and Inflammation in Patients with

PNH," Dr. Ilene Weitz, et al.


-- "Eculizumab Reduces Pulmonary Hypertension Through Inhibition of

Hemolysis-Associated Nitric Oxide Consumption in Patients With

Paroxysmal Nocturnal Hemoglobinuria," Dr. Anita Hill, et al.


The following abstracts will be presented in poster sessions on Monday, December 8, 2008.

-- "Safety and Efficacy of the Terminal Complement Inhibitor

Eculizumab in Japanese Patients with Paroxysmal Nocturnal

Hemoglobinuria: AEGIS Phase II Clinical Study Results," Dr. Yuzuru

Kanakura, et al.


-- "Modification of the Eculizumab Dose to Successfully Manage

Intravascular Breakthrough Hemolysis in Patients with Paroxysmal

Nocturnal Hemoglobinuria," Dr. Richard Kelly, et al.


-- "Effect of Reducing Intravascular Hemolysis on Ferritin Homeostasis

in Eculizumab Treated Paroxysmal Nocturnal Hemoglobinuria (PNH)

Patients," Dr. Alexander Roeth, et al.


The following abstracts will be presented in poster sessions on Sunday, December 7, 2008.

-- "Successful Treatment of Atypical Hemolytic Uremic Syndrome with

the Complement Inhibitor Eculizumab," Jens Nuernberger, et al.


-- "Long-term Efficacy of the Terminal Complement Inhibitor Eculizumab

in a Patient with Cold Agglutinin Disease (CAD)," Dr. Alexander

Roeth, et al.


The following abstract will be presented as an on-line publication.

-- "Efficacy of Eculizumab in a Plasmatherapy-Dependent Patient with

Atypical Hemolytic Uremic Syndrome with C3 mutation Following

Plasmatherapy Withdrawal," Dr Valerie Chatelet et al.

About Soliris

Soliris is the first product approved for the treatment of patients with PNH in the U.S. and Europe. PNH is a rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. In patients with PNH, hemolysis can cause life-threatening thromboses, recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria). Soliris, or eculizumab, is the only treatment that blocks this hemolysis.

Important Safety Information

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, nasopharyngitis (a runny nose), back pain and nausea.

The U.S. product label for Soliris also includes a boxed warning: "Soliris increases the risk of meningococcal infections. Vaccinate patients with a meningococcal vaccine at least two weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use. Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary." During clinical studies, two out of 196 vaccinated PNH patients treated with Soliris experienced a serious meningococcal infection.

Please see full prescribing information at

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. The Company is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer and autoimmune disorders. In March 2007, the FDA granted marketing approval for the Company's first product, Soliris for all patients with PNH. In June 2007, the European Commission granted marketing approval for Soliris in the European Union for all patients with PNH. The Company is evaluating other potential indications for Soliris, as well as other formulations of eculizumab for additional clinical indications. In addition, Alexion is pursuing development of an anti-CD200 monoclonal antibody as a treatment for patients with cancer, and evaluating development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at:


SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. USC researchers identify key mechanism that regulates the development of stem cells into neurons
2. Cornell researchers study showing evidence of a major environmental trigger for autism
3. Maastricht University researchers produce neural fingerprint of speech recognition
4. Researchers aim to over-stress already taxed mantle cell lymphoma cells
5. Researchers discover new risk factor for cardiovascular disease, and a way to control it
6. First Study of War-Related Mental Disorders Among Iraqis 10 Years Post-Gulf War Published by Researchers at Wayne State University and Basrah University, Iraq
7. Researchers find predictive tests and early treatment delay progression of blood cell cancer
8. Researchers describe how chronic inflammation can lead to stomach cancer
9. Researchers ID Genetic Markers for Esophageal Cancer
10. Researchers identify mechanism, possible drug treatment for tumors in neurofibromatosis
11. Cancer requires support from immune system to develop, UT Southwestern researchers report
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... San Francisco, California (PRWEB) , ... November 27, 2015 , ... ... 1969 Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of ... 1969 at the Canterbury House at the University of Michigan in Ann Arbor. The ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point Recovery, ... together on Thanksgiving Day to share the things that they are most grateful ... Point YouTube channel, patients displayed what they wrote on index cards, describing the ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
Breaking Medicine Technology: